Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD

CME

Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: December 20, 2022

Expiration: December 20, 2023

Erin Michos
Erin Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Muthiah Vaduganathan
Muthiah Vaduganathan, MD, MPH

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to manage residual cardiovascular risk patients with CVD, CKD, and T2DM?

2.

Betty is a patient recently diagnosed with HF. Her eGFR is 70 mL/m/1.73m2 and a urine albumin creatinine ratio (UACR) is 350 mg/g. What is her risk for CKD progression?

3.

Which of the following is an action of aldosterone that leads to cardiac disease?

4.

Which of the following is true regarding MRAs?

5.

What do the KDIGO guideline recommend regarding the use of MRAs?